Knife River Corporation (NYSE:KNF) today announced the acquisition of Donaldson Brothers Ready Mix, a prominent aggregates-based supplier in western Montana.
Kandal M Venture (NASDAQ:FMFC) today reported financial results for the first half of fiscal 2026, covering the six months ended September 30, 2025.
Pfizer (NYSE:PFE) and Valneva (NASDAQ:VALN) today announced topline results from the Phase 3 VALOR study evaluating their 6-valent OspA-based Lyme disease vaccine candidate, PF-07307405.
Sealed Air (NYSE:SEE) today announced that it has received all required regulatory approvals for its pending acquisition by funds affiliated with Clayton, Dubilier & Rice (CD&R).
Talphera (NASDAQ:TLPH) today reported financial results for the fourth quarter and full year ended December 31, 2025, detailing the fiscal costs of its ongoing transition into a specialized developer of hospital-based therapies.
Envoy Medical (NASDAQ:COCH) today reported its financial and operational results for the fiscal year ended December 31, 2025, marking a year of significant regulatory progress and balance sheet restructuring.
Avalo Therapeutics (NASDAQ:AVTX), a clinical-stage biotechnology company focused on developing interleukin-1β (IL-1β)-targeting therapies for immune-mediated inflammatory diseases, reported its financial results for the full year ended December 31, 2025.
Cabaletta Bio (NASDAQ:CABA) today reported financial results for the fourth quarter and full year ended December 31, 2025, providing a definitive timeline for the regulatory submission of its lead product candidate.
Xilio Therapeutics (NASDAQ:XLO) today reported its financial results for the fourth quarter and full year ended December 31, 2025, detailing a year of disciplined platform validation and pipeline expansion.
Ondas Holdings (NASDAQ:ONDS) today reported a landmark financial performance for the fourth quarter and full year ended December 31, 2025, marking its transition from an early-stage innovator to a high-scale industrial technology leader.
Cheer Holding (NASDAQ:CHR) officially filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, revealing a year of financial consolidation and strategic preparation.
Arbutus Biopharma (NASDAQ:ABUS) today reported a landmark set of financial and clinical results for the fourth quarter and full year ended December 31, 2025.
